AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01315353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Cryotherapy
Description: Participants had cervical cryotherapy within 7 days after study entry. The cryotherapy consists of two 3-minute freezes separated by 5 minutes of thawing.
Study NCT01315353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop Electrosurgical Excision Procedure (LEEP)
Description: Loop Electrosurgical Excision Procedure (LEEP): Participants found to have CIN2+ by biopsy had LEEP, an electro-surgical procedure used to treat high-grade cervical dysplasia.
Study NCT00425802 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rituximab
Study NCT00425802 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Study NCT00425802 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclosporine
Study NCT00425802 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fludarabine phosphate
Study NCT00425802 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: mycophenolate mofetil
Study NCT00425802 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Study NCT00425802 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: total-body irradiation
Study NCT00985764 — intervention group
Intervention type: PROCEDURE
Intervention: cesarean delivery
Study NCT01000285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT01000285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT01000285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study NCT01000285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT01000285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT01000285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT01000285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Study NCT02662101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exsalt SD7, Exsalt T7 Wound Dressing
Study NCT04248660 — intervention group
Intervention type: OTHER
Intervention: uterine artery doppler measurement
Description: The effect of delivery type on changes in uterine blood flow will be investigated.~Doppler results groups will be defined according to the effect of deviations in uterine blood flow on neonatal and perinatal results.
Study NCT04585776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT04585776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered SC
Study NCT03622619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimel Antibacterial Manuka+ Dry Eye Drops
Description: Leptospermum sp Honey 165mg/g
Study NCT03622619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra Lubricating Eye Drops
Description: Polyethylene glycol 400 0.4% and propylene glycol 0.3%
Study NCT03531944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community pharmacist-involved collaborative care
Description: Community pharmacist-involved collaborative care in the management of individuals with type 2 diabetes mellitus
Study NCT03531944 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care with physician and as needed visit to the nurse
Study NCT02936128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TruSkin
Study NCT02936128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound Cover
Study NCT01108107 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: 130 mg/m2 intravenously on day 1 of a 3-weekly cycle
Study NCT01108107 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: 2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
Study NCT01108107 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Panitumumab
Description: 9 mg/kg intravenously on day 1 of a 3-weekly cycle
Study NCT02720367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
Description: TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.
Study NCT01696942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimzia
Description: 400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks
Study NCT01696942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: mesalamine 800 mg orally three times daily
Study NCT04816331 — intervention group
Intervention type: OTHER
Intervention: Medical records and clinical measurements
Description: Medical records and clinical measurements: Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management will be collected. Therapeutic Hypothermia treatment including initiation, duration and clinical examination, and investigations such as scans. In addition, clinical data will include medication, neurological (paediatric developmental psychologist assessment and Bayley Scales of Infant and Toddler Development) and multiorgan examination.~Questionnaires for caregivers to assess social-emotional and adaptive domains.~Tissue samples analysis and processing: Samples of blood, urine and saliva will be used for laboratory testing.~Biomarker correlation with Multiorgan outcomes using statistical analysis: Data collected from medical records, clinical measurements, questionnaires, and tissue processing will be analysed using SPSS software for statistical analysis and modelling.
Study NCT01413854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: One tablet two times daily during four weeks
Study NCT01413854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: 50 mg, two times daily (oral adm.) during four weeks
Study NCT04062968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video education
Description: Prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos .
Study NCT00688103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETN Alone
Description: etanercept (25 mg, twice/week, s.c.)
Study NCT00688103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETN+MTX
Description: etanercept (25 mg, twice/week, s.c.) combined with methotrexate (6-8 mg/week)
Study NCT02697994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile Water
Description: 0.1 ml intracutaneous sterile water injections into the skin surrounding the Michaelis rhomboid over the sacral area.
Study NCT02697994 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dry Injections
Description: dry injections into the skin surrounding the Michaelis rhomboid over the sacral area.
Study NCT02937233 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine
Study NCT02937233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02866500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life survey/ dental statement
Description: Assessment of oral state and patients quality of life before radiotherapy and along treatment for oral cancer
Study NCT01809496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational Counseling
Study NCT01809496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Counseling
Study NCT01809496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Centered Counseling
Study NCT02502799 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Early Intervention
Description: Adolescents receive 5 individual sessions designed to strengthen the following skills: problem-solving, resisting peer pressure, and coping with emotions. Parents join portions of 3 sessions.
Study NCT02502799 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Training with Adolescent Cognitive Behavioral Therapy
Description: Participants receive 12 family sessions with individual adolescent, parent, and joint adolescent and parent time. Includes additional parent training in behavioral modification, adolescent and parent contracting, and adolescent decision-making skills.
Study NCT02502799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Adolescents will receive methylphenidate.
Study NCT04199897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Succrose rinsing
Description: Sucrose rinsing 7-8 times a day for 14 days
Study NCT04199897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Succrose rinsing
Description: Sucrose rinsing 7-8 times a day for 14 days
Study NCT04199897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic lozenges
Description: Probiotic lozenges 2 times a day for 35 days
Study NCT04199897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges
Description: Probiotic lozenges 2 times a day for 35 days
Study NCT04199897 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: xylitol rinsing
Description: Xylitol rinsing 7-8 times a day for 14 days
Study NCT04199897 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo lozenges 2 times a day for 35 days
Study NCT04199897 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets
Description: Placebo lozenges 2 times a day for 35 days
Study NCT05353946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: Optimal stent expansion by IVUS-guided PCI.
Study NCT01851954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: IV clarithromycin infusion
Study NCT00894153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy plus p53
Description: chemotherapy plus p53
Study NCT00894153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: chemotherapy
Study NCT00894153 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy
Study NCT02330146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCT-01
Study NCT02330146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01377597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study NCT01416415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video education on proper eye drop instillation technique
Description: The video is approximately seven minutes long and teaches the Robert Ritch method of instilling eye drops.
Study NCT01416415 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo video education on healthy eating tips
Description: The video is approximately seven minutes long and teaches tips to promote healthy eating.
Study NCT02871856 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Low dose CT
Description: low-dose screening CT of chest for lung cancer detection
Study NCT01149356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given orally
Study NCT01149356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Given orally
Study NCT01149356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given orally
Study NCT01149356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given subcutaneously to premenopausal patients
Study NCT01149356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Given subcutaneously to premenopausal patients
Study NCT00530907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 5.3 mg/kg by mouth daily x 28 days
Study NCT00530907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 2.5 mg/kg by vein over 90 minutes every 2 weeks
Study NCT03368469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: The Soterix Medical 1×1 Low Intensity Transcranial DC Stimulator Model 1300A is an investigational device manufactured by Soterix Medical, Inc. (New York, NY, USA). It is designed for use in noninvasive transcranial stimulation of the brain by delivering low-intensity electrical current to the scalp through two electrodes.
Study NCT03224923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 60mg
Description: twice daily
Study NCT03224923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60mg
Description: twice daily
Study NCT03224923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75mg
Description: once daily
Study NCT03224923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: once daily
Study NCT03439254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (10 mg)
Description: Tablets administered orally once daily.
Study NCT03439254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (10 mg to 25 mg)
Description: Tablets administered orally once daily.
Study NCT03439254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally once daily.
Study NCT02334501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Study NCT02334501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Study NCT02429674 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TranS-C and IPT-A
Description: The goal of IPT-A is to decrease depressive symptoms by focusing on current interpersonal difficulties and helping the adolescent improve his or her relationships and interpersonal interactions. This is accomplished through psychoeducation about the adolescent's depression and its link to interpersonal relationships, review of the adolescent's significant relationships, identification of interpersonal problem areas on which to focus the treatment, development of interpersonal problem solving and communication skills, and role-playing. The sleep disturbances intervention will include several modules selected because they are successful treatments for insomnia, and/or may help promote adherence to some of the recommendations related to sleep.
Study NCT00831285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: food product
Description: food product given at one of six visits
Study NCT00831285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: food product
Description: food product given at one of six visits
Study NCT00458887 — intervention group
Intervention type: PROCEDURE
Intervention: management of therapy complications
Description: Undergo hearing tests
Study NCT02303522 — intervention group
Intervention type: OTHER
Intervention: Other: not applicable - observational study
Description: No intervention exists as this is a retrospective observational study
Study NCT01945541 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body Composition Monitoring
Description: Pre- and postoperative measurements of body composition (intracellular and extracellular water content)via bioimpedance spectroscopy
Study NCT01789645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative group
Description: The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
Study NCT01789645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical group
Description: The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
Study NCT00691405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 5 mcg BID
Study NCT00691405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 15 mcg BID
Study NCT00691405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 25 mcg BID
Study NCT00691405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation solution BID
Study NCT03193957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept PFS and Autoinjector
Study NCT03193957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector
Description: Autoinjector
Study NCT04043299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100% Oxygen
Description: High flow cylinder oxygen will be administered to women with fetal distress during labor
Study NCT04043299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 21% oxygen
Description: High flow cylinder packaged medical air will be administered to women with fetal distress during labr
Study NCT01342861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Addition of protein (milky food in the breakfast)
Description: The main purpose of this study is to evaluate the efficacy of additional protein (adding milky food to the breakfast) in order to deliver an optimized protein and energy intake of 15.75 g and 559 Kcal, respectively.
Study NCT01342861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Addition of protein (milky food in the breakfast)
Description: The main purpose of this study is to evaluate the efficacy of additional protein (adding milky food to the breakfast) in order to deliver an optimized protein and energy intake of 15.75 g and 559 Kcal, respectively.
Study NCT00691405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 15 mcg QD
Study NCT00691405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 25 mcg QD
Study NCT00691405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 50 mcg QD
Study NCT00691405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation solution QD
Study NCT04364243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digitally supported home exercises
Description: The training will comprise of 9 sessions (3 weekly) Each of the training sessions will last 20 minutes. This will result in a cumulative total intervention exercise time of 180 minutes.
Study NCT02782689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kit Biflex
Description: Two-layer reusable compression system
Study NCT02782689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Profore
Description: Four-layer compression system
Study NCT01877772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Trephination
Description: For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
Study NCT01877772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will undergo standard rotator cuff repair.
Study NCT00850603 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
Description: 0.5 mL, Subcutaneous
Study NCT00850603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
Description: 0.1 mL, Subcutaneous
Study NCT00850603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
Description: 0.05 mL, Intradermal
Study NCT00850603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
Description: 0.1 mL, Intradermal
Study NCT00850603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
Description: 0.15 mL, Intradermal
Study NCT01849159 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cells
Description: Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution
Study NCT01849159 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reference therapy: 400 mL of 0.9% NaCl solution